186 material Form 8-K filings that 173 companies we cover made with the SEC in April 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
VITAS Healthcare, a wholly owned subsidiary of Chemed, completed its $85 million purchase of substantially all hospice operations and an assisted living facility from Covenant Health and Community Services, effective April 17, 2024. The purchase was made with cash on hand, and the filing does not report financial results from the acquired operations.
Purchase price: $85 million, structured as an asset purchase, funded with cash on hand
Covenant hospice operations span the Florida panhandle and Alabama, including Pensacola, Tallahassee, Panama City and Dothan markets
Transaction was first announced on March 13, 2024 and closed effective April 17, 2024
Corcept Therapeutics entered into a sublease on April 12, 2024 for about 50,632 rentable square feet at 101 Redwood Shores Parkway in Redwood City, California, with the sublessor Zuora, Inc. The lease runs from about July 1, 2024 through June 30, 2030, creating a new direct financial obligation. The filing discloses base rent averaging $1.4 million a year plus $240,000 a year for shared amenities, a modest commitment that the filing does not compare with Corcept's financial results.
Sublease dated April 12, 2024 with Zuora, Inc. for about 50,632 rentable square feet
Term expected to start on or around July 1, 2024 and end June 30, 2030
Base rent averages $1.4 million annually, plus $240,000 annually for shared amenities space
Full sublease to be filed with a Form 10-Q; Corcept intends to seek confidential treatment for some terms
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.